Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

Nature Medicine

Volumn 18, Issue 10, 2012, Pages 1503-1510

  Kwong, Lawrence N ^a,b   Costello, James C ^c   Liu, Huiyun ^a   Jiang, Shan ^a,b   Helms, Timothy L ^b   Langsdorf, Aliete E ^a   Jakubosky, David ^a   Genovese, Giannicola ^a,b   Muller, Florian L ^a,b   Jeong, Joseph H ^a   Bender, Ryan P ^a   Chu, Gerald C ^a,d   Flaherty, Keith T ^e   Wargo, Jennifer A ^e   Collins, James J ^c,f   Chin, Lynda ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Boston University   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SELUMETINIB; TRAMETINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BENZIMIDAZOLES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; DOXYCYCLINE; FEMALE; GENES, RAS; HUMANS; MELANOMA; MICE; MICE, KNOCKOUT; MICE, NUDE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84870289371     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2941     Document Type: Article

References (45)

1. Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. CancerNatl. Rev. 7, 295-308 (2007).
2. Jakob, J.A. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4013-4023 (2011).
3. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
4. Gilmartin, A.G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
5. Bollag, G. et al. Clinical effcacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
6. Flaherty, K.T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367, 107-114 (2012).
7. Falchook, G.S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789 (2012).
8. Kirkwood, J.M. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567 (2012).
9. Ascierto, P.A. et al. Effcacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J. Clin. Oncol. 30, suppl; abstr 8511 (2012).
10. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
11. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
12. Heidorn, S.J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
13. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
14. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
15. Paraiso, K.H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730 (2010).
16. Morris, M.K., Saez-Rodriguez, J., Sorger, P.K. & Lauffenburger, D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 49, 3216-3224 (2010).
17. Sachs, K., Gifford, D., Jaakkola, T., Sorger, P. & Lauffenburger, D.A. Bayesian network approach to cell signaling pathway modeling. Sci. STKE 2002, pe38 (2002).
18. Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifes RUNX1 as tumor suppressor in T-ALL. Nat. Med 18, 436-440 (2012).
19. Belcastro, V. et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 39, 8677-8688 (2011).
20. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999).
21. Yeh, T.C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583 (2007).
22. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
23. Pratilas, C.A. et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106, 4519-4524 (2009).
24. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
25. Luo, J. et al. A genome-wide RNAi screen identifes multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
26. VanBrocklin, M.W., Verhaegen, M., Soengas, M.S. & Holmen, S.L. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res. 69, 1985-1994 (2009).
27. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
28. Fry, D.W. et al. Specifc inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438 (2004).
29. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770-1783 (2006).
30. Lens, S.M., Voest, E.E. & Medema, R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. CancerNatl. Rev. 10, 825-841 (2010).
31. Joseph, E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903-14908 (2010).
32. Packer, L.M., East, P., Reis-Filho, J.S. & Marais, R. Identifcation of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 22, 785-798 (2009).
33. Hoefich, K.P. et al. Antitumor effcacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042-3051 (2009).
34. Dry, J.R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273 (2010).
35. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010).
36. Haigis, K.M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600-608 (2008).
37. Adjei, A.A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008).
38. Schwartz, G.K. et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br. J. Cancer 104, 1862-1868 (2011).
39. Paweletz, C.P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
40. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
41. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profling of human tumors. Proc. Natl. Acad. Sci. USA 107, 8352-8356 (2010).
42. Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
43. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
44. Faith, J.J. et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profles. PLoS Biol. 5, e8 (2007).
45. Opsahl, T., Agneessens, F. & Skvoretz, J. Node centrality in weighted networks: Generalizing degree and shortest paths. Soc. Networks 32, 245-251 (2010).